Aurobindo Pharma Ltd (AUROPHARMA) Stock Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AUROPHARMA Analyst Ratings

Moderate Buy

3 Buy

0 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Aurobindo

Pharma Ltd

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AUROPHARMA Stock 12 Month Forecast

Average Price Target

₹1,430.00

▲(21.25%Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Aurobindo Pharma Ltd in the last 3 months. The average price target is ₹1,430.00 with a high forecast of ₹1,700.00 and a low forecast of ₹1,140.00. The average price target represents a 21.25% change from the last price of ₹1,179.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1056":"₹1,056","1701":"₹1,701","1217.25":"₹1,217.3","1378.5":"₹1,378.5","1539.75":"₹1,539.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.70K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.43K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.14K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1056,1217.25,1378.5,1539.75,1701],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Jan<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1265.6000000000001,1301.8000000000002,1338,1374.2,1410.4,1446.6000000000001,1482.8000000000002,1519,1555.2,1591.4,1627.6,1663.8000000000002,{"y":1700,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1244.8307692307694,1260.2615384615385,1275.6923076923078,1291.123076923077,1306.5538461538463,1321.9846153846154,1337.4153846153847,1352.8461538461538,1368.2769230769231,1383.7076923076922,1399.1384615384616,1414.5692307692307,{"y":1430,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1229.4,1222.523076923077,1215.646153846154,1208.769230769231,1201.8923076923077,1195.0153846153846,1188.1384615384616,1181.2615384615385,1174.3846153846155,1167.5076923076924,1160.6307692307691,1153.753846153846,1146.876923076923,{"y":1140,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1152.45,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1187,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1212.15,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1432.25,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1553.2,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1438.55,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1396,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1255.25,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1351.4,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1351.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1171.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1057.95,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1229.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹1,700

Average Price Target₹1,430

Lowest Price Target₹1,140

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kunal DhameshaMacquarie

Macquarie

₹1,700

Buy

44.15%

Upside

Reiterated

03/28/25

Macquarie Reiterates Outperform Rating on Aurobindo Pharma (ARBP:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,700.00 price target on Aurobindo Pharma (ARBP:IN).

Vivek Agrawal CFACiti

Citi

₹1,285→₹1,140

Sell

-3.34%

Downside

Reiterated

03/26/25

Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,140 at CitiCiti analyst Vivek Agrawal lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,140.00 (from INR1,285.00) while maintaining a Sell rating.

Damayanti KeraiHSBC

HSBC

₹1,580

Buy

33.97%

Upside

Reiterated

03/21/25

HSBC Reiterates Buy Rating on Aurobindo Pharma (ARBP:IN)HSBC analyst Damayanti Kerai reiterated a Buy rating and INR1,580.00 price target on Aurobindo Pharma (ARBP:IN).

Shyam SrinivasanGoldman Sachs

Goldman Sachs

₹1,475→₹1,300

Buy

10.23%

Upside

Reiterated

03/04/25

Aurobindo Pharma (ARBP:IN) PT Lowered to INR1,300 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan lowered the price target on Aurobindo Pharma (ARBP:IN) to INR1,300.00 (from INR1,475.00) while maintaining a Buy rating.

Abdulkader PuranwalaICICI Securities

ICICI Securities

₹1,470→₹1,445

Buy

22.53%

Upside

Reiterated

02/10/25

Aurobindo Pharma Ltd. (ARBP:IN) PT Lowered to INR1,445 at ICICI SecuritiesICICI Securities analyst Abdulkader Puranwala lowered the price target on Aurobindo Pharma Ltd. (ARBP:IN) to INR1,445.00 (from INR1,470.00) while maintaining a Buy (1) rating.

Kunal LakhanCLSA

CLSA

₹1,540→₹1,400

Buy

18.71%

Upside

Upgraded

01/23/25

CLSA Upgrades Aurobindo Pharma (ARBP:IN) to Outperform (2)CLSA analyst Kunal Lakhan upgraded Aurobindo Pharma (ARBP:IN) from Hold (3) to Outperform (2) with a price target of INR1,400.00 (from INR1,540.00).

Unknown AnalystKotak Mahindra

Not Ranked

Kotak Mahindra

₹1,225

Sell

3.87%

Upside

Reiterated

12/29/24

Kotak reiterates Sell (4) Rating on Aurobindo Pharma Ltd. (ARBP:IN)Kotak analyst Kumar Gaurav reiterated a Sell (4) rating and INR1,225.00 price target on Aurobindo Pharma Ltd. (ARBP:IN).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kunal DhameshaMacquarie

Macquarie

₹1,700

Buy

44.15%

Upside

Reiterated

03/28/25

Macquarie Reiterates Outperform Rating on Aurobindo Pharma (ARBP:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,700.00 price target on Aurobindo Pharma (ARBP:IN).

Vivek Agrawal CFACiti

Citi

₹1,285→₹1,140

Sell

-3.34%

Downside

Reiterated

03/26/25

Damayanti KeraiHSBC

HSBC

₹1,580

Buy

33.97%

Upside

Reiterated

03/21/25

HSBC Reiterates Buy Rating on Aurobindo Pharma (ARBP:IN)HSBC analyst Damayanti Kerai reiterated a Buy rating and INR1,580.00 price target on Aurobindo Pharma (ARBP:IN).

Shyam SrinivasanGoldman Sachs

Goldman Sachs

₹1,475→₹1,300

Buy

10.23%

Upside

Reiterated

03/04/25

Abdulkader PuranwalaICICI Securities

ICICI Securities

₹1,470→₹1,445

Buy

22.53%

Upside

Reiterated

02/10/25

Kunal LakhanCLSA

CLSA

₹1,540→₹1,400

Buy

18.71%

Upside

Upgraded

01/23/25

Unknown AnalystKotak Mahindra

Not Ranked

Kotak Mahindra

₹1,225

Sell

3.87%

Upside

Reiterated

12/29/24

Kotak reiterates Sell (4) Rating on Aurobindo Pharma Ltd. (ARBP:IN)Kotak analyst Kumar Gaurav reiterated a Sell (4) rating and INR1,225.00 price target on Aurobindo Pharma Ltd. (ARBP:IN).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Aurobindo Pharma Ltd

1 Month

xxx

Success Rate

1/2 ratings generated profit

Average Return

+1.55%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.55% per trade.

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+5.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +5.90% per trade.

1 Year

Anubhav Agarwal CFAUBS

Success Rate

1/1 ratings generated profit

Average Return

+7.30%

reiterated a sell rating last month

Copying Anubhav Agarwal CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +7.30% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+5.90%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +5.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUROPHARMA Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AUROPHARMA has received 11 Buy Ratings, 1 Hold Ratings, and 4 Sell Ratings. AUROPHARMA average Analyst price target in the past 3 months is 1,430.00.

Each month's total comprises the sum of three months' worth of ratings.

AUROPHARMA Financial Forecast

AUROPHARMA Earnings Forecast

Next quarter’s earnings estimate for AUROPHARMA is ₹17.41 with a range of ₹17.35 to ₹17.46. The previous quarter’s EPS was ₹15.56. AUROPHARMA beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year AUROPHARMA has Preformed in-line its overall industry.

AUROPHARMA Sales Forecast

Next quarter’s sales forecast for AUROPHARMA is ₹85.50B with a range of ₹85.50B to ₹85.50B. The previous quarter’s sales results were ₹83.82B. AUROPHARMA beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year AUROPHARMA has Outperformed its overall industry.

AUROPHARMA Stock Forecast FAQ

What is IN:AUROPHARMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Aurobindo Pharma Ltd’s 12-month average price target is 1,430.00.

What is IN:AUROPHARMA’s upside potential, based on the analysts’ average price target?

Aurobindo Pharma Ltd has 21.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Aurobindo Pharma Ltd a Buy, Sell or Hold?

Aurobindo Pharma Ltd has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 0 hold ratings and 1 sell ratings.

What is Aurobindo Pharma Ltd’s share price target?

The average share price target for Aurobindo Pharma Ltd is 1,430.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹1,700.00 ,and the lowest forecast is ₹1,140.00. The average share price target represents 21.25% Increase from the current price of ₹1,179.35.

What do analysts say about Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Aurobindo Pharma Ltd?

To buy shares of IN:AUROPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Aurobindo Pharma Ltd (AUROPHARMA) Stock Forecast & Price Target

AUROPHARMA Analyst Ratings

AUROPHARMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Aurobindo Pharma Ltd

AUROPHARMA Analyst Recommendation Trends

AUROPHARMA Financial Forecast

AUROPHARMA Earnings Forecast

AUROPHARMA Sales Forecast

AUROPHARMA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts